Prosecution Insights
Last updated: November 20, 2026

Sean E Aeder, USPTO Patent Examiner

Listed by the USPTO as AEDER, SEAN E

Tech Center 1600 • Art Units: 1600 1642 1652 1654 1671

This examiner grants 57% of resolved cases

Analysis

AEDER, SEAN E is a USPTO patent examiner in tech center 1600 and art unit 1600. The profile covers 1438 resolved cases, with a 57.0% allowance rate and a median of 1124 days to allowance. The 19.8% interview lift indicates a higher observed allowance outcome for cases involving interviews.

The listed companies are Novartis AG, Bristol-Myers Squibb Company, and Biontech SE. The listed firms are CASIMIR JONES, S.C., EpiMED LLC, and Fox Rothschild, LLP. The large resolved-case record supports using the measures as meaningful prosecution context. The allowance rate indicates that applicants should prepare for substantive examination, while the interview result supports considering interviews as one component of response strategy.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

57.0%
Allow Rate
-3.0% vs TC avg
1,526
Total Applications
+19.8%
Interview Lift
1124
Avg Prosecution Days
Based on 1438 resolved cases, 2023–2026

Rejection Statute Breakdown

14.7%
§101 Eligibility
17.2%
§102 Novelty
26.4%
§103 Obviousness
27.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18167295 DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER Final Rejection Genentech, Inc.
18359569 LDL RECEPTOR-DIRECTED BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS Non-Final OA The Regents of the University of California
17918479 TARGETING ABCB5 IN GLIOBLASTOMA MULTIFORME Non-Final OA The Brigham and Women's Hospital, Inc.
18683858 OFATUMUMAB FOR TREATING PEDIATRIC MS Non-Final OA NOVARTIS AG
17753632 TREATMENT OF RMS BY SWITCHING THERAPY Non-Final OA Novartis AG
18042441 METHODS OF TREATING CANCER BY ADMINISTERING A PD-1 INHIBITOR Non-Final OA Regeneron Pharmaceuticals, Inc.
18746198 DETECTING NEOPLASM Non-Final OA Mayo Foundation for Medical Education and Research
18720518 METHODS OF USING AN ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY AND ANTI-TAU ANTIBODY Non-Final OA WASHINGTON UNIVERSITY
17775233 TARGETING CIRCULAR PCMTD1 IN LEUKEMIAS WITH P53 MUTATIONS AND/OR BCR/ABL FUSIONS Final Rejection Ohio State Innovation Foundation
18284590 MODULATING PRODUCT QUALITY OF ASYMMETRIC MULTISPECIFIC ANTIBODIES THROUGH THE USE OF TEMPERATURE Non-Final OA AMGEN INC.
18030223 ENHANCEMENT OF ANTI-TUMOR PHAGOCYTOSIS Non-Final OA The Board of Trustees of the Leland Stanford Junior University
18528327 NATURAL KILLER T CELL LIGAND LOADED EXTRACELLULAR NANOVESICLE AND AUTOLOGOUS ANTI-CANCER VACCINE FOR HEMATOLOGIC MALIGNANCIES COMPRISING THE SAME Non-Final OA SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
18010580 BIOMARKER BASED PATIENT SELECTION FOR PROTEASOME INHIBITOR TREATMENT Non-Final OA University of Utah Research Foundation
18193917 METHODS FOR THE DETECTION AND TREATMENT OF LUNG CANCER Non-Final OA Board of Regents, The University of Texas System
17779716 COMPOSITIONS AND METHODS FOR TREATING DISEASES AND CONDITIONS BY DEPLETION OF MITOCHONDRIAL OR GENOMIC DNA FROM CIRCULATION Non-Final OA Cedars-Sinai Medical Center
18463743 TIM-3 ANTAGONISTS FOR THE TREATMENT AND DIAGNOSIS OF CANCERS Non-Final OA Bristol-Myers Squibb Company
17763614 COMPOSITE BIOMARKER FOR CANCER THERAPY Final Rejection Bristol-Myers Squibb Company
18247878 TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES Non-Final OA Iovance Biotherapeutics, Inc.
18558066 NEUTRALIZING ANTI- SARS-COV-2 ANTIBODIES AND METHODS OF USE THEREOF Non-Final OA The Rockefeller University
17296506 METHODS FOR TREATING DYSREGULATED LIPID METABOLISM Final Rejection DENALI THERAPEUTICS INC.
18392902 METHODS FOR DELIVERING ANTIBODIES TO THE FETAL CIRCULATION Final Rejection The Children's Medical Center Corporation
18292232 COMPOSITIONS AND METHODS FOR TREATMENT OF MELANOMA Non-Final OA BioNTech SE
18549346 MULTISPECIFIC BINDING AGENTS AGAINST CD40 AND CD137 IN THERAPY Non-Final OA BIONTECH SE
18402642 ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES AND USES THEREOF Non-Final OA BioAtla, Inc.
17781652 USE OF CELL FREE NUCLEOSOMES AS BIOMARKERS Final Rejection Belgian Volition SRL
18498508 THERAPEUTIC METHODS AND USES FOR ANTIBODIES TO HUMAN MASP-3 Final Rejection Novo Nordisk Healthcare AG

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Sean E Aeder's allowance rate?

57.0% of resolved applications examined by Sean E Aeder were allowed (1,438 resolved cases), compared with 36.5% across Art Unit 1600 over the last five years.

Does an interview help with examiner Sean E Aeder?

This examiner's interview lift is +19.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Sean E Aeder take to allow a patent?

Applications allowed by Sean E Aeder took 1,124 days on average from filing to allowance.

Which art unit does examiner Sean E Aeder work in?

Sean E Aeder examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month